2/7/2026

Janusmed kön och genus

Janusmed kön och genus – durvalumab

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Durvalumab

Durvalumab

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Imfinzi (durvalumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-07-02, cited 2026-01-30]

  2. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer. 2007;110(7):1532-41.

  3. Li C, Lei S, Ding L, Xu Y, Wu X, Wang H et al. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023;136(13):1583-1590.

  4. Lampimukhi M, Qassim T, Venu R, Pakhala N, Mylavarapu S, Perera T et al. A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma. Cureus. 2023;15(11):e49429.

  5. Ledenko M, Antwi SO, Arima S, Driscoll J, Furuse J, Klümpen HJ et al. Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials. Front Oncol. 2022;12:963753.

  6. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919-1929.

  7. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol. 2020;15(2):288-293.

  8. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-1939.

  9. Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408.

  10. Yamanaka Y, Okuno Y, Kamisako K, Okazaki Y, Nakanishi K, Sanada Y et al. Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real-World Evidence. Cancer Med. 2024;13(24):e70480.

  11. Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.

  12. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.

  13. Reinmuth N, Goldman JW, Chen Y, Hotta K, Trukhin D, Statsenko G et al. Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study. Clin Lung Cancer. 2025;26(8):626-641.

  14. Mikami T, Liaw B, Asada M, Niimura T, Zamami Y, Green-LaRoche D et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol. 2021;152(1):135-144.

  15. Yang F, Shay C, Abousaud M, Tang C, Li Y, Qin Z, Saba NF, Teng Y. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. J Exp Clin Cancer Res. 2023 Jan 5;42(1):4

  1. Imfinzi (durvalumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-07-02, cited 2026-01-30]
  2. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer. 2007;110(7):1532-41.
  3. Li C, Lei S, Ding L, Xu Y, Wu X, Wang H et al. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023;136(13):1583-1590.
  4. Lampimukhi M, Qassim T, Venu R, Pakhala N, Mylavarapu S, Perera T et al. A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma. Cureus. 2023;15(11):e49429.
  5. Ledenko M, Antwi SO, Arima S, Driscoll J, Furuse J, Klümpen HJ et al. Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials. Front Oncol. 2022;12:963753.
  6. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919-1929.
  7. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol. 2020;15(2):288-293.
  8. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-1939.
  9. Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408.
  10. Yamanaka Y, Okuno Y, Kamisako K, Okazaki Y, Nakanishi K, Sanada Y et al. Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real-World Evidence. Cancer Med. 2024;13(24):e70480.
  11. Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.
  12. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.
  13. Reinmuth N, Goldman JW, Chen Y, Hotta K, Trukhin D, Statsenko G et al. Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study. Clin Lung Cancer. 2025;26(8):626-641.
  14. Mikami T, Liaw B, Asada M, Niimura T, Zamami Y, Green-LaRoche D et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol. 2021;152(1):135-144.
  15. Yang F, Shay C, Abousaud M, Tang C, Li Y, Qin Z, Saba NF, Teng Y. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. J Exp Clin Cancer Res. 2023 Jan 5;42(1):4